文献速递类风湿关节炎

甲氨蝶呤依从性检测方法的开发与验证

Development and validation of a methotrexate adherence assay.
PubMed 文献 · Ann Rheum Dis · 2019-06-05

该研究开发并验证了一种基于HPLC-SRM-MS检测血浆甲氨蝶呤浓度的客观依从性检测方法。通过20例RA患者药代动力学评估和50例真实世界样本验证模型,并在138例观察性队列中确立检测敏感性,结果显示该方法能准确识别MTX依从者,敏感性达95%。

要点

  • HPLC-SRM-MS血浆检测可客观识别甲氨蝶呤依从性,敏感性95%。
  • 约40%RA患者对MTX不依从,可能影响疗效并导致升级生物制剂。
  • 该验证后的客观检测可临床用于识别需要依从性支持的患者。

核心结论

  • HPLC-SRM-MS血浆分析能准确检测甲氨蝶呤依从性,验证后的客观检测可临床用于识别需要依从性支持的患者。

研究设计与样本

  • 研究对20例RA患者进行6天甲氨蝶呤药代动力学评估,以直接观察治疗为参考标准。
  • 使用50例真实世界患者自我报告给药时间的独立血浆样本进行药代动力学模型验证。
  • 在138例观察性队列研究中,经检测优化后确立检测依从性的敏感性。

主要发现

  • 开发并验证了二室药代动力学模型,模拟描述了7天内检测甲氨蝶呤所需的敏感性。
  • 后续检测优化和样本复测确认所有患者均被正确识别为甲氨蝶呤依从者。
  • 使用真实世界样本,检测敏感性为95%。

关键数值与推荐

  • 甲氨蝶呤为RA一线治疗,每周口服低剂量7.5-25 mg。
  • 约40%患者不依从。
  • 检测敏感性为95%。

临床怎么用

  • 该客观检测可易于在临床使用,以识别需要依从性支持的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The first-line therapy for rheumatoid arthritis (RA) is weekly oral methotrexate (MTX) at low dosages (7.5-25 mg/week). However, ~40% of patients are non-adherent which may explain why some do not respond and need to start more expensive biological therapies. To monitor adherence more accurately and develop strategies to improve it, a validated objective MTX adherence test is required. OBJECTIVE: To develop and validate the diagnostic accuracy of a novel MTX adherence assay using high-performance liquid chromatography-selected reaction monitoring- mass spectrometry (HPLC-SRM-MS) based biochemical analysis of drug levels. METHODS: 20 patients with RA underwent MTX pharmacokinetic assessment using HPLC-SRM-MS MTX plasma concentration analysis over a 6-day period. Directly observed therapy was the reference standard. Pharmacokinetic model validation was performed using independent plasma samples from real-world patients (n=50) with self-reported times of drug administration. Following assay optimisation, the sensitivity of the assay to detect adherence was established using samples from an observational cohort study (n=138). RESULTS: A two-compartment pharmacokinetic model was developed and validated. Simulations described the sensitivity required for MTX detection over 7 days; subsequent assay optimisation and retesting of samples confirmed that all patients were correctly identified as MTX adherers. Using real-world samples, the assays sensitivity was 95%. CONCLUSION: Non-adherence to MTX is common and can have a significant effect on disease activity. HPLC-SRM-MS plasma analysis accurately detects MTX adherence. The validated objective test could easily be used in clinic to identify patients requiring adherence support.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Bluett J, Riba-Garcia I, Verstappen SMM, et al. Development and validation of a methotrexate adherence assay. Ann Rheum Dis. 2019. PMID: 31167761. doi:10.1136/annrheumdis-2019-215446

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。